NCT01413048 is a Phase 3 clinical trial of Carvedilol 25mg in Essential Hypertension, sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd.

Who is sponsoring NCT01413048?

NCT01413048 is sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd.

What drugs are being tested in NCT01413048?

Interventions in NCT01413048: Carvedilol 25mg, AGSCT101 12.5mg.

What condition does NCT01413048 study?

NCT01413048 studies Essential Hypertension.

Is NCT01413048 still recruiting?

NCT01413048 is currently status unknown. Last updated 8 August 2011.

Last reviewed 2011-08-08 · How we verify

NCT01413048

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 Versus Carvedilol in Patient With Stage 1 to 2 Essential Hypertension

Status unknown Phase 3 Last updated 8 August 2011

What this trial tests

Phase 3 trial testing Carvedilol 25mg in Essential Hypertension in 260 participants. Status unknown.

Timeline

1 January 2011

Primary endpoint
1 March 2012

1 September 2012

Quick facts

Lead sponsor	Ahn-Gook Pharmaceuticals Co.,Ltd
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	260
Start date	1 January 2011
Primary completion	1 March 2012
Estimated completion	1 September 2012
Sites	1 location across South Korea

Drugs / interventions tested

Carvedilol 25mg — full drug profile →
AGSCT101 12.5mg — full drug profile →

Conditions studied

Essential Hypertension — all drugs for Essential Hypertension →

Sponsor

Ahn-Gook Pharmaceuticals Co.,Ltd — full company profile →

Who can join

19 and older, any sex, with Essential Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline in diastolic blood pressure (DBP)
Time frame: 8 weeks

Sponsor's own description

The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in patient with stage 1 to 2 essential hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Carvedilol 25mg

Trials testing the same drug.

NCT03576664 — Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans · EARLY_PHASE1 · completed

Other recruiting trials for Essential Hypertension

Currently open trials in the same condition.

NCT07282145 — Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers · Phase 1 · recruiting
NCT06778239 — Childhood-Onset Essential Hypertension Natural History Study · recruiting
NCT07051811 — To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension · NA · recruiting
NCT06643819 — Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A · Phase 3 · recruiting
NCT05880056 — Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian P · Phase 4 · recruiting

Other Ahn-Gook Pharmaceuticals Co.,Ltd trials

Trials by the same sponsor.

NCT07198347 — Efficacy and Safety of AG2001 in Patients With Acute Bronchitis · Phase 3 · not yet recruiting
NCT05503953 — Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Contr · Phase 3 · unknown
NCT04686643 — Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension · Phase 3 · unknown
NCT05206578 — Study to Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia · Phase 3 · unknown
NCT04554303 — Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01413048 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahn-Gook Pharmaceuticals Co.,Ltd
Last refreshed: 8 August 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01413048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing